Clinical Trials Browser

Fallopian Tube Neoplasms × dalotuzumab × Gastrointestinal × Clear all

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms